NCT06158438已完成不适用
Safety and Efficacy of the BTL-754 Device for Laser Skin Resurfacing Treatment of the Face
BTL Industries Ltd.2 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2023年11月16日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 56
- 试验地点
- 2
- 主要终点
- Assess reduction of wrinkle severity according to the Fitzpatrick Wrinkle and Elastosis Scale
研究概览
简要总结
This study will evaluate the clinical safety and the performance of the BTL-754 device (equipped with the 754-4 applicator) for reduction of facial wrinkles by the means of laser skin resurfacing treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 22 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects over 22 years of age seeking treatment for reduction of wrinkles.
- •Presence of clearly visible wrinkles in the treated area when the face is relaxed as deemed appropriate by the Investigator.
- •Subjects are willing to have polycarbonate eye shields placed for study treatment.
- •Subjects should be able to understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form.
- •Subjects are willing to maintain the usual skin care regimen during study participation with the exception when protocol specified ointments, moisturizers, and cleansers are required during the healing stage. Sunblock is required throughout the subject's participation in the study.
- •Subjects are willing to abstain from other facial cosmetic procedures during the study; examples include, but are not limited to: laser or chemical resurfacing, dermabrasion, neuromodulator and/or filler injections, aesthetic facial surgery, etc.
- •Subjects are willing and able to comply with protocol requirements, including obtaining study-required digital photographs and assessments, post-care instructions, and returning for follow-up visits.
- •Women of childbearing potential are required to use birth control measures.
排除标准
- •Intolerance to anesthetic based agents
- •Infectious disease
- •Connective tissue disease
- •Propensity for keloid formations
- •Immunocompromised or compromised healing
- •Use of long-standing systemic steroids (e.g. Prednisone, Dexamethasone)
- •Pregnant, planning to become pregnant, or breast feeding during the study
- •Use of isotretinoin (e.g. Accutane, Sotret, Claravis, Amnesteem) within the past year
- •Medical condition that may affect wound healing
- •Any unstable medical or psychiatric conditions
- •Major systemic diseases - e.g. uncontrolled Diabetes mellitus
- •Photosensitivity, medications affecting sensitivity to light
- •Corticosteroids or injections of the treated area within the last 90 days, long-term corticosteroids use
- •Electronic implants (such as cardiac pacemakers, defibrillators and neurostimulators)
- •Blepharoplasty (in case of eyelid treatment)
- •Anticoagulant therapy, bleeding disorders
- •Application within 4 to 6 months after radiotherapy
- •Known or suspected malignancy, history of cancer or any type of malignancy
- •Febrile conditions, serious illness, chronic infection
- •Deep vein thrombosis
- •Subject has had concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety and effectiveness of the study treatment method.
- •Subject is enrolled in another investigational (drug or device) clinical trial or has participated in any other investigational study within 30 days prior to consent that can interfere with this study's assessments as per investigator's discretion.
- •Subject has undergone a facelift procedure, IPL, laser, microneedling, chemical peels, dermal fillers, BOTOX® or other toxins within 6 months prior to the screening visit.
- •Tattoo(s) or permanent make-up in the intended treatment area.
- •Subject has used, within 30 days prior to screening or plans to use during study participation, Accutane, Retinol, or any medication that can cause dermal hypersensitivity.
- •Any other disease or condition at the investigator discretion that may pose risk to the patient or compromise the study.
结局指标
主要结局
Assess reduction of wrinkle severity according to the Fitzpatrick Wrinkle and Elastosis Scale
时间窗: 5 months
The primary efficacy outcome measure is a statistically significant reduction of at least 1.0 score in the average score of Fitzpatrick Wrinkle and Elastosis Scale score according to at least 2 out of 3 blinded dermatologists at 3-months follow-up compared to baseline.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Safety and Efficacy of the BTL-785F Device for Non-invasive Reduction of Submental FatSkin LaxityNCT05831332BTL Industries Ltd.56
已完成
不适用
BTL-785F Device for Non-invasive Lipolysis and Circumference Reduction of the AbdomenFat BurnNCT04621019BTL Industries Ltd.70
已完成
不适用
BTL-785F Device for Non-invasive Facial Rejuvenation in Patients Injected With Botulinum ToxinWrinkleNCT05524766BTL Industries Ltd.13
已完成
不适用
BTL-785F Device for Improving the Structure of Facial MusclesWrinkleNCT05524740BTL Industries Ltd.10
已完成
不适用
BTL-785F Device for Non-invasive Reduction of WrinklesWrinkleNCT05519124BTL Industries Ltd.20